Xvivo Perfusion AB (publ) (XVIVO.ST)
Gothenburg, SE
Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.55% | -6.86% | +0.87% | +47.63% | +49.22% | +52.84% | -7.42% | -3.05% | -12.82% | +361.33% | +1,356.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-1.3% Q1'26: +10.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-85.3% Q1'26: +394.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-5.4% Q1'26: +27.1% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+10.2% ★ Q1'26: +13.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+2.6% Q1'26: +5.5% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.4% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.55× Q1'26: 0.96× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
120.25M
est: 124.84M (-3.7%)
|
138.18M
est: 141.00M (-2.0%)
|
148.34M
est: 147.50M (+0.6%)
|
187.87M
est: 182.33M (+3.0%)
|
220.84M
est: 222.88M (-0.9%)
|
179.86M
est: 187.00M (-3.8%)
|
258.39M
est: 261.30M (-1.1%)
|
415.29M
est: 400.81M (+3.6%)
|
597.54M
est: 698.73M (-14.5%)
|
822.42M
est: 808.16M (+1.8%)
|
812.17M
est: 800.85M (+1.4%)
|
1.00B
991.74M – 1.03B
+25.3% YoY
|
1.33B
1.24B – 1.46B
+32.5% YoY
|
1.68B
1.67B – 1.68B
+26.1% YoY
|
2.18B
2.09B – 2.33B
+30.0% YoY
|
2.85B
2.73B – 3.04B
+30.8% YoY
|
| EBITDA |
19.14M
est: 9.88M (+93.7%)
|
16.21M
est: 11.16M (+45.2%)
|
22.37M
est: 11.68M (+91.6%)
|
20.25M
est: 14.43M (+40.3%)
|
16.81M
est: 17.64M (-4.7%)
|
-43.33M
est: 14.80M (-392.7%)
|
39.20M
est: 20.68M (+89.5%)
|
39.21M
est: 31.73M (+23.6%)
|
35.05M
est: 115.32M (-69.6%)
|
272.97M
est: 133.39M (+104.6%)
|
153.14M
est: 132.18M (+15.9%)
|
165.57M
163.69M – 169.40M
+25.3% YoY
|
219.31M
205.21M – 241.71M
+32.5% YoY
|
276.58M
275.83M – 277.33M
+26.1% YoY
|
359.57M
344.60M – 384.16M
+30.0% YoY
|
470.23M
450.65M – 502.38M
+30.8% YoY
|
| EBIT |
7.50M
est: 622.2K (+1,105.1%)
|
3.09M
est: 702.7K (+340.3%)
|
7.45M
est: 735.1K (+913.7%)
|
17.63M
est: 908.7K (+1,839.7%)
|
5.58M
est: 1.11M (+401.9%)
|
-56.90M
est: 932.0K (-6,205.4%)
|
6.94M
est: 1.30M (+433.0%)
|
23.41M
est: 2.00M (+1,071.8%)
|
4.19M
est: 61.81M (-93.2%)
|
205.55M
est: 71.49M (+187.5%)
|
82.93M
est: 70.84M (+17.1%)
|
88.73M
87.73M – 90.79M
+25.3% YoY
|
117.53M
109.98M – 129.54M
+32.5% YoY
|
148.23M
147.83M – 148.63M
+26.1% YoY
|
192.71M
184.68M – 205.88M
+30.0% YoY
|
252.01M
241.52M – 269.24M
+30.8% YoY
|
| Net Income |
5.13M
est: 13.01M (-60.6%)
|
1.50M
est: 3.17M (-52.6%)
|
6.26M
est: 8.49M (-26.3%)
|
12.69M
est: 18.90M (-32.9%)
|
4.94M
est: 15.18M (-67.5%)
|
-43.74M
est: 4.43M (-1,086.5%)
|
8.15M
est: 8.48M (-3.9%)
|
18.43M
est: 47.99M (-61.6%)
|
91.82M
est: 120.74M (-23.9%)
|
172.18M
est: 162.18M (+6.2%)
|
25.16M
est: 35.81M (-29.7%)
|
107.49M
94.38M – 153.18M
+200.2% YoY
|
209.81M
183.14M – 230.43M
+95.2% YoY
|
311.22M
288.31M – 381.52M
+48.3% YoY
|
488.82M
462.36M – 532.27M
+57.1% YoY
|
792.08M
749.20M – 862.49M
+62.0% YoY
|
| SGA |
45.21M
est: 65.22M (-30.7%)
|
60.20M
est: 73.67M (-18.3%)
|
63.75M
est: 77.06M (-17.3%)
|
70.47M
est: 95.26M (-26.0%)
|
85.53M
est: 116.45M (-26.6%)
|
90.24M
est: 97.70M (-7.6%)
|
153.38M
est: 136.53M (+12.3%)
|
223.38M
est: 209.42M (+6.7%)
|
309.21M
est: 359.84M (-14.1%)
|
379.77M
est: 416.20M (-8.8%)
|
377.09M
est: 412.44M (-8.6%)
|
516.61M
510.75M – 528.58M
+25.3% YoY
|
684.30M
640.32M – 754.19M
+32.5% YoY
|
863.00M
860.66M – 865.34M
+26.1% YoY
|
1.12B
1.08B – 1.20B
+30.0% YoY
|
1.47B
1.41B – 1.57B
+30.8% YoY
|
| EPS |
0.24
est: 0.41 (-41.6%)
|
0.07
est: 0.10 (-30.0%)
|
0.25
est: 0.27 (-6.8%)
|
0.48
est: 0.60 (-19.6%)
|
0.19
est: 0.48 (-60.4%)
|
-1.61
est: 0.14 (-1,250.0%)
|
0.28
est: 0.27 (+4.5%)
|
0.62
est: 1.52 (-59.1%)
|
3.07
est: 3.93 (-21.8%)
|
5.47
est: 5.05 (+8.3%)
|
0.80
est: 1.12 (-28.3%)
|
3.71
2.99 – 4.85
+232.8% YoY
|
6.77
5.80 – 7.30
+82.4% YoY
|
10.26
9.14 – 12.09
+51.6% YoY
|
15.49
14.65 – 16.87
+50.9% YoY
|
25.10
23.74 – 27.33
+62.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X HealthTech ETF HEAL | 0.68% | 204.1K | 0.50% |
| 2 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.11% | 360.9K | 0.23% |
| 3 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.11% | 360.9K | 0.23% |
| 4 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.09% | 977.7K | 0.40% |
| 5 | iShares MSCI Europe Small-Cap ETF IEUS | 0.05% | 82.3K | 0.41% |
| 6 | State Street SPDR S&P International Small Cap ETF GWX | 0.05% | 408.7K | 0.40% |
| 7 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.05% | 1.59M | 0.30% |
| 8 | iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE | 0.03% | 155.8K | 0.10% |
| 9 | Schwab International Small-Cap Equity ETF SCHC | 0.03% | 1.55M | 0.06% |
| 10 | UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW | 0.03% | 231.6K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christoffer Rosenblad | Chief Executive Officer | 6M | male |
| Jaya Tiwari | Senior Vice President of Medical Affairs | — | female |
| Johan Holmstrom | Senior Vice President of Commercial Europe & RoW | — | male |
| Kristoffer Nordstrom | CFO and Senior VP of Corporate Strategy & Business Development | — | male |
| Lena Hagman | Chief Operating Officer & Deputy Chief Executive Officer | — | female |
| Magnus Nilsson | Senior Advisor | — | — |
| Mark Reade | Senior Vice President of North America | — | male |
| Ylva Vihoj | Senior Vice President of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for XVIVO.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
